Our findings that hypoxia increases resistance to 3-BrPA in KRAS-mutant wt p53 tumor cells rather than in those with NRAS mutation, and the reversal of this resistance with Prima-1 is important, because no effective single clinical therapy has been consistently achieved to treat tumors linked to KRAS [28, 37, 38] or NRAS mutations [28, 40, 49–51]. Here, NRAS is linked to neoplasm.